2seventy bio

company

About

2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment.

  • 251 - 500

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$20M
Industries
Biotechnology,Genetics,Health Care,Therapeutics
Founded date
Jan 1, 2021
Number Of Employee
251 - 500
Operating Status
Active

2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline.

It was established in Cambridge, Massachusetts in 2021.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$190M
2seventy bio has raised a total of $190M in funding over 2 rounds. Their latest funding was raised on Jan 6, 2023 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 6, 2023 Post-IPO Equity $20M 1 Regeneron Detail
Mar 16, 2022 Post-IPO Equity $170M 2 Detail

Investments

Number of Investments
Number of Lead Investments
5
0
2seventy bio has made 5 investments. Their most recent investment was on Feb 15, 2022, when Cohere raised $159M.
Date Company Name
Round Money Raised Industry Lead Investor
Feb 15, 2022 Cohere
Series B $159M Artificial Intelligence
Jan 17, 2022 Wayve
Series B $200M Artificial Intelligence
Sep 7, 2021 Cohere
Series A $40M Artificial Intelligence
Jun 8, 2021 Waabi
Series A $100M Artificial Intelligence
Jul 1, 2019 Wayve
Series A $20M Artificial Intelligence

Investors

Number of Lead Investors
Number of Investors
1
3
2seventy bio is funded by 3 investors. Regeneron and Newtyn Management are the most recent investors.
Investor Name Lead Investor Funding Round
Regeneron Yes Post-IPO Equity
Newtyn Management Post-IPO Equity
Nick Leschly & family Post-IPO Equity